Double Medical Technology Inc. (SHE:002901)
China · Delayed Price · Currency is CNY 42.02
-1.84 (-4.20%)
Apr 24, 2026, 3:04 PM CST
Double Medical Technology Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
Operating Revenue | 2,601 | 2,119 | 1,525 | 1,428 | 1,989 |
Other Revenue | - | 16.7 | 8.39 | 5.94 | 5.02 |
| 2,601 | 2,136 | 1,533 | 1,434 | 1,994 | |
Revenue Growth (YoY) | 21.79% | 39.30% | 6.91% | -28.09% | 25.68% |
Cost of Revenue | 767.19 | 710.15 | 541.52 | 344.6 | 319.12 |
Gross Profit | 1,834 | 1,425 | 991.6 | 1,089 | 1,675 |
Selling, General & Admin | 844.75 | 769.03 | 690.5 | 788.18 | 746.94 |
Research & Development | 331.2 | 306.87 | 285.28 | 256.72 | 167.07 |
Other Operating Expenses | -61.34 | 9.1 | -2.51 | 15.77 | 27.52 |
Operating Expenses | 1,115 | 1,091 | 972.13 | 1,059 | 957.77 |
Operating Income | 719.07 | 334.38 | 19.47 | 30.9 | 717.45 |
Interest Expense | - | -6.49 | -7.16 | -3.1 | -0.55 |
Interest & Investment Income | 4.72 | 44.78 | 39.65 | 37.23 | 34.63 |
Currency Exchange Gain (Loss) | - | -11.35 | 0.77 | 7.62 | -5.87 |
Other Non Operating Income (Expenses) | 21.08 | -0.16 | -0.54 | -0.32 | -0.2 |
EBT Excluding Unusual Items | 744.86 | 361.16 | 52.19 | 72.33 | 745.45 |
Impairment of Goodwill | - | -0.5 | -0.86 | -1.37 | -0.91 |
Gain (Loss) on Sale of Investments | 49.41 | 3.11 | 5.6 | 1.77 | 1.22 |
Gain (Loss) on Sale of Assets | 0.62 | 0.27 | 0.3 | -1.73 | -0 |
Asset Writedown | -64.86 | -0.43 | -0.02 | -0.54 | -0.03 |
Legal Settlements | - | - | - | - | -19.1 |
Other Unusual Items | - | 64.81 | 42.51 | 77 | 75.88 |
Pretax Income | 730.04 | 428.41 | 99.72 | 147.46 | 802.51 |
Income Tax Expense | 93.17 | 43.12 | 13.4 | 37.89 | 111.01 |
Earnings From Continuing Operations | 636.88 | 385.29 | 86.32 | 109.57 | 691.5 |
Minority Interest in Earnings | -37.25 | -28.49 | -27.36 | -17.01 | -18.19 |
Net Income | 599.63 | 356.8 | 58.96 | 92.56 | 673.31 |
Net Income to Common | 599.63 | 356.8 | 58.96 | 92.56 | 673.31 |
Net Income Growth | 68.06% | 505.16% | -36.30% | -86.25% | 11.16% |
Shares Outstanding (Basic) | 408 | 415 | 421 | 421 | 401 |
Shares Outstanding (Diluted) | 408 | 415 | 421 | 421 | 403 |
Shares Change (YoY) | -1.68% | -1.49% | 0.10% | 4.35% | 0.52% |
EPS (Basic) | 1.47 | 0.86 | 0.14 | 0.22 | 1.68 |
EPS (Diluted) | 1.47 | 0.86 | 0.14 | 0.22 | 1.67 |
EPS Growth | 70.93% | 514.29% | -36.36% | -86.83% | 10.60% |
Free Cash Flow | 697.83 | 171.84 | -231.82 | -156.63 | 438.15 |
Free Cash Flow Per Share | 1.71 | 0.41 | -0.55 | -0.37 | 1.09 |
Dividend Per Share | - | 0.500 | 0.250 | - | 0.500 |
Dividend Growth | - | 100.00% | - | - | -37.50% |
Gross Margin | 70.50% | 66.75% | 64.68% | 75.97% | 84.00% |
Operating Margin | 27.65% | 15.66% | 1.27% | 2.15% | 35.97% |
Profit Margin | 23.05% | 16.71% | 3.85% | 6.45% | 33.76% |
Free Cash Flow Margin | 26.83% | 8.05% | -15.12% | -10.92% | 21.97% |
EBITDA | 846.42 | 446.79 | 121.28 | 117.12 | 782.07 |
EBITDA Margin | 32.54% | 20.92% | 7.91% | 8.17% | 39.22% |
D&A For EBITDA | 127.35 | 112.42 | 101.81 | 86.22 | 64.62 |
EBIT | 719.07 | 334.38 | 19.47 | 30.9 | 717.45 |
EBIT Margin | 27.65% | 15.66% | 1.27% | 2.15% | 35.97% |
Effective Tax Rate | 12.76% | 10.06% | 13.44% | 25.70% | 13.83% |
Revenue as Reported | - | 2,136 | 1,533 | 1,434 | 1,994 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.